This trial is testing a new drug to see if it can help people with obesity lose weight by reducing hunger, cravings, and stress.
3 Primary · 3 Secondary · Reporting Duration: week 0, 4, 8, 12
Experimental Treatment
Non-Treatment Group
96 Total Participants · 2 Treatment Groups
Primary Treatment: GLP-1 analogue - semaglutide · Has Placebo Group · Phase 1
Age 18 - 55 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 66.7% |
California | 33.3% |
18 - 65 | 100.0% |
The Yale Stress Center: Yale University | 100.0% |
Did not meet criteria | 66.7% |
Met criteria | 33.3% |
1 | 100.0% |